A vaccine Pancreatic cancer It can be used as a promising new treatment.
Memorial Sloan Kettering Cancer Center (MSK) in New York, an experimental approach, a vaccine based on messenger RNA (mRNA) through messenger RNA (mRNA) “continue to show potential” to reduce the risk of disease return after surgery Potential press release.
result Phase 1 clinical trialPublished in Nature, it reveals that the vaccine triggers an immune response in a small patient group.
Cancer vaccines show encouraging results for some patients
The release said that this immune cell activation lasted nearly four years after treatment.
Patients accepted vaccine and showed that immune system responses were more likely to remain cancer-free during three years of follow-up.
MSK reported in a press release that the results of the Phase I clinical trial “continue to show potential.” (iStock)
Vinod Balachandran, MD, MD, principal investigator of the trial and senior study author of MSK, said he is optimistic about the efficacy of the treatment.
“We found that using RNA vaccine technology, we can teach the immune system to recognize Pancreatic cancerthis immune response may last for many years. ” he said.
“The ability to trigger a strong, lasting immune response is a necessary feature of any cancer vaccine.”
Since pancreatic cancer is “hard to treat,” Balachandran expressed surprise at the response of some patients’ immune systems.
“We encourage us to see what our approach can teach Immune system To identify pancreatic cancer, the immune response is effective and may affect the patient. ” he said.
“The ability to trigger a strong, lasting immune response is a necessary feature of any cancer vaccine.”
“Despite the discovery promising, these vaccines are still in the early stages of testing,” Balachandran said.
The team is planning a larger study to “further test the vaccine that removes pancreatic cancer by surgery.”
The therapeutic vaccine targets the early stages of cancer, and the tumor can be removed surgically and does not spread. (iStock)
Among the 16 participants, the vaccine stimulated the immune response in half. Personalize cancer vaccines for each participant to target specific proteins found in the form of disease.
The patient also accepted Immunotherapy drugs (Atezolizumab) and standard chemotherapy after surgery.
Click here to get the Fox News app
The researchers say that therapeutic cancer vaccines like this, called autoenoate, are designed to treat cancer rather than prevent cancer, “recognize cancer cells as foreign.”
Patients who have an immune response to the vaccine are more likely to reduce cancer risk through three years of examination. (iStock)
The vaccine aims to target early stages of cancers that have not yet been transmitted, which can be surgically removed to “help delay or prevent recurrence.”
Balachandran notes that this approach may also be applied to other forms of cancer.
“If you can do this in pancreatic cancer, in theory, you might be able to develop a therapeutic vaccine for other cancer types.”
“For pancreatic cancer patients, our latest results continue to support the use of personalized mRNA vaccines to target neoantigens in each patient’s tumor,” he said.
“If you can do this in pancreatic cancer, in theory, you might be able to develop a therapeutic vaccine for other cancer types.”
For more health articles, please visit www.foxnews.com/health
Pancreatic cancer remains one of the deadliest cancers because she is still alive for five years five years after diagnosis, according to MSK and the American Cancer Society.
Click here to sign up for our health newsletter
Common Therapies Like chemotherapy, radiation and immunotherapy are “basically ineffective” for pancreatic cancer, which makes new therapies “deeply needed”, MSK said.
